Dondero, A., Pastorino, F., Della Chiesa, M., Corrias, M.V., Morandi, F., Pistoia, V., et al. (2016) PD-L1 Expression in Metastatic Neuroblastoma as an Additional Mechanism for Limiting Immune Surveillance. Oncoimmunology, 5, e1064578.
https://doi.org/10.1080/2162402X.2015.1064578

has been cited by the following article:

• TITLE: N-Myc Inhibition: Advances in Neuroblastoma Treatment

  AUTHORS: Md Kamrul Hasan

  KEYWORDS: Neuroblastoma, N-Myc, PI3K/mTOR, PARP1, PD-L1, HAUSP

  JOURNAL NAME: CellBio, Vol.6 No.3, September 30, 2017

  ABSTRACT: Neuroblastoma (NBL) is one of the most common solid tumors and around 15% of cancer mortality in children. Amplification of the N-Myc proto-oncogene is strongly correlated with advanced disease and poor clinical outcome in NBL. Recent studies described that ubiquitin-specific protease 7 (USP7; also known as HAUSP) interacts with N-Myc, induces deubiquitination and subsequent stabilization of N-Myc that in-turn potentiates N-Myc function, and treatment with the HAUSP inhibitor (P22077) blocked such effects.